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S6 Journal of Thoracic Oncology Vol. 11 No. 2SIn CT-based lung cancer screening and incidentally
detected indeterminate pulmonary nodules, radiomics
has shown value in improving diagnostic accuracy to
discriminate cancer from benign pulmonary nodules. We
have analyzed data from the National Lung Screening
Trial, NLST, to identify subjects with cancerous and
benign nodules, and have organized them into cohorts
based on their screening history. Patients who are
diagnosed with cancer following a prior nodule-negative
screen have signiﬁcantly worse outcome than patients
who develop cancer following a prior nodule-positive/
cancer-negative screen. In cohorts of patients with
nodules not diagnosed as cancer in the ﬁrst screen, we
have identiﬁed signiﬁcant radiomic features that can
discriminate those who will subsequently develop can-
cer from those that remain benign with an accuracy of
80%, and this can be the basis for a “radiomics risk
score” to predict subsequent cancer development.
However, even the seemingly large “big data” NLST data
set is underpowered once cohorts are assembled with
similar histories, and co-variates are accounted for. So-
lutions to the problem of generating sufﬁciently powered
data sets include capturing the radiomic data at the point
of care (i.e. by the radiologists) and inter-institutional
sharing of images, data, features and algorithms, which
have yet to be reliably implemented.From bench to bedside to beam:
Hippocampal-sparing during cranial
irradiationVinai Gondi Northwestern Medicine Cancer
Center, Warrenville, ILWhole-brain radiotherapy either therapeutically for
brain metastases or prophylactically for small-cell lung
cancer has been associated with cognitive toxicity, in the
form of decline primarily in list-learning recall as well as
patient-reported cognitive functioning. Emerging evi-
dence suggests that the pathogenesis of radiotherapy-
induced cognitive deﬁcits may involve radiation-
induced injury to proliferating neural stem cells in the
subgranular zone of the hippocampus. Conformal
avoidance of this hippocampal neural stem cell
compartment during whole-brain radiotherapy using
intensity-modulated radiotherapy has been proposed as
an approach to preserving hippocampal neurogenesis
and thus preventing or mitigating radiotherapy-related
cognitive toxicity.
Promising results as compared to historical controls
were observed in RTOG 0933, a phase II study of hip-
pocampal avoidant WBRT for patients with brain me-
tastases. Validation of these results in a phase III settingis being pursued through NRG CC001, a phase III trial of
memantine plus whole-brain radiotherapy with or
without hippocampal avoidance for brain metastases.
Extrapolation of these results to the setting of prophy-
lactic cranial irradiation for small cell lung cancer is
being explored through NRG CC003, a randomized phase
II/III trial of prophylactic cranial irradiation with or
without hippocampal avoidance for small cell lung can-
cer. Both trials are currently activated and accruing
patients.
This presentation will review the biology and radio-
sensitivity of the hippocampal neural stem cell compart-
ment and prior and ongoing clinical studies to
corroborate these preclinical observations using
advanced radiotherapy techniques.Primary and adaptive resistance to
checkpoint blockade in lung cancerPeter Hammerman Dana-Farber Cancer
Institute, Boston, MAThe incorporation of immunotherapies, and most
notably immune checkpoint inhibitors, into the man-
agement of non-small cell lung cancer (NSCLC) has led to
a paradigm shift in the management of patients with
advanced disease. While PD1 antagonists have been
shown to be superior to standard chemotherapy for
subjects with progressive advanced disease many other
immunomodulatory agents are currently under investi-
gation as single agents or in combination with other
therapies.
While the lung cancer community has made great
strides in identifying genomic alterations in cancers
which are associated with speciﬁc therapeutic vulnera-
bilities, our knowledge regarding predictive biomarkers
for immunotherapies is limited. It remains the case that
only a minority of patients respond to PD1:PDL1 an-
tagonists, and for those who do, resistance to therapy
develops over time.
Here, I will present data describing our efforts in
proﬁling mouse models and patient specimens to
describe two modes of resistance to PD1:PDL1 ther-
apy. The ﬁrst centers on primary non-response in
patients with KRAS mutated lung cancers, tumors
which typically display high rates of somatic muta-
tions. I will present data demonstrating that within
KRAS mutated lung adenocarcinoma tumors with
concurrent loss of STK11/LKB1 display an adverse
immune microenvironment for PD1:PDL1 therapy. I
will discuss speciﬁc features of this immune micro-
environment and suggest strategies to overcome pri-
mary resistance.
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in immune cells in the tumor microenvironment which
occur over time in response to PD1:PDL1 therapy. These
changes, which include upregulation of alternate im-
mune checkpoints, lead to eventual failure of PD1:PDL1
blockade. I will show that TIM3 is a targetable biomarker
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Lung cancer is the leading cause of cancer death in the
United States, with more than 158,000 deaths expected
in 2015, approximately 90% of which will have been
caused by cigarette smoking. Worldwide in 2012, there
were 1,589,800 deaths from lung cancer. Cigarette
smoking accounts for 80% of the worldwide lung can-
cer burden in males and at least 50% in females. Our
approach to lung cancer prevention is based on an
understanding of the carcinogens in tobacco smoke and
their mechanisms of action. This leads to carcinogen
and toxicant biomarkers that have the potential to
identify susceptible individuals at a young age so they
can be targeted for intensive smoking cessation therapy
and surveillance. We have developed a panel of urinary
tobacco smoke carcinogen and toxicant metabolites that
can be used to quantify exposure in cigarette smokers.
The panel consists of nicotine metabolites comprising
nearly 90% of the nicotine dose (nicotine, cotinine, 3’-
hydroxycotinine and their glucuronides, and nicotine-
N-oxide), total NNAL (comprised of free NNAL and its
glucuronides – metabolites of the tobacco-speciﬁc lung
carcinogen NNK), total NNN (comprised of free NNN
and its glucuronides – metabolites of the tobacco-
speciﬁc carcinogen NNN), phenanthrene tetraol and
3’-hydroxyphenanthrene (metabolites of the represen-
tative polycyclic aromatic hydrocarbon phenanthrene),
mercapturic acid metabolites of the volatile toxicants
and carcinogens 1,3-butadiene, acrolein, crotonalde-
hyde, and benzene, 8-iso-PGF2a (a representativeF2-isoprostane resulting from oxidative damage), and
PGEM, a prostaglandin E2 metabolite related to
inﬂammation. Multiple studies by our group and others
have clearly demonstrated that this panel of metabo-
lites is related to exposure to tobacco smoke. Thus,
most of these metabolites decrease upon cessation of
cigarette smoking. We have participated in collabora-
tive prospective epidemiologic studies to determine
whether these urinary biomarkers are also related to
lung cancer risk. The Shanghai Cohort Study of 18,244
Chinese men collected and stored urine samples in the
1980s. We analyzed urine samples from 325 lung can-
cer cases and 356 controls, all smokers from this study,
and found that the smoking-adjusted odds ratios (95%
CIs) for lung cancer for the highest relative to the
lowest quartile of urinary total nicotine, total cotinine,
total 3’-hydroxycotinine, total nicotine equivalents and
total NNAL were 3.03 (1.80-5.10), 4.70 (2.61-8.46),
4.26 (2.37-7.68), 4.71 (2.61-8.52), and 3.15 (1.86-5.33),
respectively (all Ptrend <0.001). We have also found that
phenanthrene tetraol, but not the mercapturic acid
metabolites of the volatile toxicants and carcinogens, is
independently related to lung cancer risk among
smokers in this study. These results demonstrate that
these urinary metabolites are risk biomarkers as well
as exposure biomarkers.
We have also used these biomarkers to investigate
potential explanations for differing risks of lung cancer
among ethnic groups. The Multiethnic Cohort Study
demonstrated that, for the same number of cigarettes
smoked, African Americans and Native Hawaiians have a
higher risk for lung cancer than Whites while Latinos and
Japanese Americans have a lower risk. We analyzed urine
samples from 300-700 subjects per group for total nico-
tine equivalents, total NNAL, phenanthrene tetraol, 3-
hydroxyphenanthrene, and the mercapturic acids of
acrolein, crotonaldehyde, and benzene. The results
demonstrated that African Americans, although smoking
fewer cigarettes per day than any of the other groups
except Latinos, had signiﬁcantly higher levels of total
nicotine equivalents, total NNAL, phenanthrene tetraol, 3-
hydroxyphenanthrene, and the benzene metabolite S-
phenylmercapturic acid compared to Whites while Japa-
nese Americans had signiﬁcantly lower levels of total
nicotine equivalents, total NNAL, and 3-hydroxyphenan-
threne than Whites. The relatively low levels of total
nicotine equivalents in the urine of the Japanese Amer-
ican smokers was related to low activity polymorphisms
in CYP2A6, the major enzyme responsible for nicotine
metabolism. These results partially explain the differing
susceptibilities to lung cancer among these ethnic groups,
but further research is necessary to fully understand the
relatively high risk of Native Hawaiians (which may be
related to their acrolein levels) or the low risk of Latinos.
